Sflt-1 in heart failure: relation with disease severity and biomarkers

References

• Accornero F, Molkentin JD. Placental growth factor as a protective paracrine effector in the heart. Trends Cardiovasc Med 2011;21:220–4.
   PubMed Web of Science ®Google Scholar
• Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P, Molkentin JD. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res 2011;109:272–80.
   PubMed Web of Science ®Google Scholar
• Andersen LB, Frederiksen-Moller B, Work HK, Dechend R, Jørgensen JS, Jensen BL, Nielsen J, Lykkedegn S, Barington T, Christesen HT. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens 2015;9:86–96.
   PubMed Web of Science ®Google Scholar
• Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67–75.
   PubMed Web of Science ®Google Scholar
• Carnevale D, Cifelli G, Mascio G, Madonna M, Sbroggiò M, Perrino C, Persico MG, Frati G, Lembo G. Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor-alpha-converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload. Circulation 2011;20:1337–50.
   Web of Science ®Google Scholar
• Carnevale D, Lembo G. Placental growth factor and cardiac inflammation. Trends Cardiovasc Med 2012;22:209–12.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, Reiter M, Duehsler B, Freidank H, Winkler K, Twerenbold R, Mueller C. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 2011;32:326–35.
   PubMed Web of Science ®Google Scholar
• Kadowaki S, Shishido T, Honda Y, Narumi T, Otaki Y, Kinoshita D, Nishiyama S, Takahashi H, Arimoto T, Miyamoto T, Watanabe T, Kubota I. Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome. Heart Vessels 2016;31:535–44.
   PubMed Web of Science ®Google Scholar
• Kameda R, Yamaoka-Tojo M, Makino A, Wakaume K, Nemoto S, Kitasato L, Shimohama T, Tojo T, Machida Y, Izumi T. Soluble fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation. Int Heart J 2013;54:133–9.
   PubMed Web of Science ®Google Scholar
• Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Mende A, Kobayashi T, Kugiyama K. Atorvastatin increases plasma soluble fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 2006;48:43–50.
   PubMed Web of Science ®Google Scholar
• Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 2011;19:386–94.
   Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Uemura S, Takeda Y, Matsui M, Okada S, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Onoue K, Kawata H, Kawakami R, Horii M, Saito Y. An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease. Intern Med 2013;52:1019–27.
   PubMed Web of Science ®Google Scholar
• McCurley A, McGraw A, Pruthi D, Jaffe IZ. Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease. Pflugers Arch 2013;465:1661–70.
   PubMed Web of Science ®Google Scholar
• McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P, Jaffe IZ. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc 2013;2:e000018.
   PubMed Web of Science ®Google Scholar
• McGraw AP, McCurley A, Preston IR, Jaffe IZ. Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep 2013;15:340.
   PubMed Web of Science ®Google Scholar
• Nakada Y, Takahama H, Kanzaki H, Sugano Y, Hasegawa T, Ohara T, Amaki M, Funada A, Yoshida A, Yasuda S, Ogawa H, Anzai T. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure. Heart Vessels 2016;31:925–31.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura S, Ishikawa SE. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 2009;131:186–91.
   PubMed Web of Science ®Google Scholar
• Nandy D, Mukhopadhyay D, Basu A. Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose. J Investig Med 2010;58:804–6.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Fujita SI, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N. Association between circulating FGF23, alpha-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels 2016;31:66–7.
   PubMed Web of Science ®Google Scholar
• Peiskerova M, Kalousova M, Danzig V, Míková B, Hodková M, Němeček E, Bani-Hani A, Ambrož D, Benáková H, Linhart A, Zima T, Tesař V. Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study. BMC Nephrol 2013;14:142. doi: 10.1186/1471-2369-14-142.: 142-14.
   PubMed Web of Science ®Google Scholar
• Rambod M, Heine GH, Seiler S, Dominic EA, Rogacev KS, Dwivedi R, Ramezani A, Wing MR, Amdur RL, Fliser D, Raj DS. Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study. Atherosclerosis 2014;236:360–5.
   PubMed Web of Science ®Google Scholar
• Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, Schratzberger P. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis 2009;206:265–9.
   PubMed Web of Science ®Google Scholar
• Searle J, Mockel M, Gwosc S, Qadri F, Albert GI, Holert F, Isbruch A, Klug L, Muller DN, Dechend R, Muller R, Vollert JO, Slagman A, Mueller C, Herse F. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro – brief report. Arterioscler Thromb Vasc Biol 2011;31:2972–4.
   PubMed Web of Science ®Google Scholar
• Shin S, Lee SH, Park S, Kang SM, Chung N, Shim WH, Cho SY, Manabe I, Jang Y. Soluble fms-like tyrosine kinase-1 and the progression of carotid intima-media thickness – 24-month follow-up study. Circ J 2010;74:2211–5.
   PubMed Web of Science ®Google Scholar
• Wollert KC. Tailored therapy for heart failure: the role of biomarkers. Eur Heart J 2012;33:2246–8.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004;44:264–70.
   PubMed Web of Science ®Google Scholar